109 filings
Page 3 of 6
8-K
avmahdcy 9ya
24 Jun 21
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
u3c302ea5usrra 4jk
16 Jun 21
Zai Lab and MacroGenics Enter Into Broad Strategic
7:43am
8-K
1q5uc
1 Jun 21
Entry into a Material Definitive Agreement
7:30am
8-K
vog7r36pn77xzv4oj
10 May 21
Zai Lab Reports First Quarter 2021 Financial Results
8:55am
8-K
uaicnv c2
23 Apr 21
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
12:29pm
8-K
fg9c2lo3h2 g1px3km
21 Apr 21
Financial Statements and Exhibits
3:00pm
8-K
zfre1
20 Apr 21
Zai Lab Announces Pricing of Public Offering of American Depositary Shares and Ordinary Shares
9:38pm
8-K
t1h0l0p
19 Apr 21
Zai Lab Announces Proposed Public Offering of American Depositary Shares
4:30pm
8-K
qpvwoqeu3r7c
13 Apr 21
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
7:45am
8-K
a4ezqqsyo8wphhvanxo
31 Mar 21
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal
7:32am
8-K
fenqli91lfug0snqr
1 Mar 21
Zai Lab Announces Financial Results
7:01am
8-K
yhgyzsj2kpfosrhl ac
11 Jan 21
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning
6:52am
8-K
bw0cgh zlv9yli
6 Jan 21
Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
4:08pm
8-K
7rsjmje3nd9b
4 Jan 21
Other Events
7:27am
6-K
6vmlu neu
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
x9i0uzkbeqbng
28 Dec 20
Zai Lab and Cullinan Oncology Announce Strategic
7:30am
6-K
97gt3e9dwj8x
1 Dec 20
Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology
7:30am
6-K
k3w vcukji1
22 Oct 20
Current report (foreign)
8:03am
6-K
d2dpu l6mxw5hmyuyqu
9 Oct 20
Current report (foreign)
9:06am
6-K
6p7w2
28 Sep 20
Zai Lab Announces Closing of Hong Kong Secondary Listing
7:52am